xT CDx
Tempus AI, Inc. · Decision date May 28, 2026
What did the FDA approve?
FDA records P210011/S004 as a supplement to PMA P210011, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 28, 2026.
FDA approval order statement
Addition of an alternative method of germline subtraction and implementing an updated MSI caller in the bioinformatics pipeline.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- May 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P210011/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- May 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210011 · Original PMA
xT CDx
P210011/S004 received
Application receipt date recorded by FDA.
P210011/S004 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P210011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011 | Tempus AI, Inc. | PMA approval | Apr 28, 2023 | FDA |
xT CDxP210011/S002 | Tempus AI, Inc. | PMA supplement | Sep 2, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tempus AI, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 600 W Chicago Ave., Suite #510, Chicago, IL, 60654
Sources and methodology
- Original FDA record: P210011/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




